Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Axitinib 5 MG
DRUG
2 trials
Sponsors
Abramson Cancer Center at Penn Medicine
, Lynkcell Europe
Conditions
Clear Cell Kidney Cancer
Colorectal Neoplasms Malignant
Kidney Cancer
Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Phase 1
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Terminated
NCT04873895
Abramson Cancer Center at Penn Medicine
Colorectal Neoplasms Malignant
Start: 2022-01-24
End: 2024-04-25
Updated: 2024-04-26
Unknown Phase
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
NCT05941637
Lynkcell Europe
Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Updated: 2024-12-31